Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-04-18
2006-04-18
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S311000, C514S314000, C514S563000, C514S568000, C514S588000, C514S635000, C562S425000, C562S426000, C562S439000, C562S440000, C562S452000, C562S455000, C546S079000, C546S152000
Reexamination Certificate
active
07030133
ABSTRACT:
The nonenzymatic glycation and crosslinking of proteins is a part of the aging process with the glycation endproducts and crosslinking of long-lived proteins increasing with age. This process is increased at elevated concentrations of reducing sugars in the blood and in the intracellular environment such as occurs with diabetes. The structural and functional integrity of the affected molecules become disturbed by these modifications and can result in severe consequences. The compounds of the present invention can be used to inhibit this process of nonenzymatic glycation and therefore to inhibit some of the ill effects caused by diabetes or by aging. The compounds are also useful for preventing premature aging, spoilage of proteins in food and can prevent discoloration of teeth.
REFERENCES:
patent: 4661579 (1987-04-01), Blöcker
patent: 4921997 (1990-05-01), Lalezari et al.
patent: 5093367 (1992-03-01), Lalezari et al.
patent: 5268500 (1993-12-01), Lalezari et al.
patent: 5272176 (1993-12-01), Ulrich et al.
patent: 5292935 (1994-03-01), Lalezari et al.
patent: 5602277 (1997-02-01), Babu et al.
patent: 5661139 (1997-08-01), Lankin
patent: 5677330 (1997-10-01), Abraham et al.
patent: 5716987 (1998-02-01), Wille
patent: 5962651 (1999-10-01), Lalezari et al.
patent: 6337350 (2002-01-01), Rahbar et al.
patent: 6589944 (2003-07-01), Rahbar
patent: 6605642 (2003-08-01), Rahbar et al.
patent: 6693106 (2004-02-01), Rahbar et al.
patent: 6787566 (2004-09-01), Rahbar
patent: 2002/0013256 (2002-01-01), Rahbar et al.
patent: 2002/0123501 (2002-09-01), Rahbar et al.
patent: 2002/0128278 (2002-09-01), Rahbar et al.
patent: 2002/0002203 (2003-01-01), Rahbar
patent: WO 92/07560 (1992-05-01), None
patent: WO 95/31192 (1995-11-01), None
patent: WO 98/55121 (1998-12-01), None
patent: WO 00/59875 (2000-10-01), None
patent: WO 00/66102 (2000-11-01), None
patent: WO 01/76584 (2001-10-01), None
patent: WO 02/072083 (2002-09-01), None
patent: WO 02/076443 (2002-10-01), None
patent: WO 04/071416 (2004-08-01), None
Al-Abed, Y. et al. “Inhibition of advanced glycation endproduct formation by acetaldehyde: Role in the cardioprotective effect of ethanol”,Proc. Natl. Acad. Sci. USA, Mar. 1999; 96:2385-2390.
Aldrich Catalog 805, 786, 8, and 3, 1994-1995.
Asif, M. et al. “An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness”,Proc. Natl. Acad. Sci., Mar. 14, 2000; 97(6):2809-2813.
Beisswenger, P.J. et al. “Metformin Reduces Systemic Methylglyoxal Levels in Type 2 Diabetes”,Diabetes, Jan. 1999; 48:198-202.
Boel, E. et al. “Diabetic Late Complications: Will Aldose Reductase Inhibitors or Inhibitors of Advanced Glycosylation Endproduct Formation Hold Promise?”,J. Diabetes and Its Complications, 1995; 9:104-129.
Booth, A.A. et al. “Thiamine Pyrophosphate and Pyridoxamine Inhibit the Formation of Antigenic Advanced Glycation End-Products: Comparison with Aminoguanidine”,Biochem. Biophys. Res. Commun., 1996; 220:113-119.
Booth, A.A. et al. “In Vitro Kinetic Studies of Formation of Antigenic Advanced Glycation End Products (AGEs)”,Journal of Biological Chemistry, Feb. 28, 1997; 272(9):5430-5437.
Calatayud, J.M., “Favorable Effects of the Lipid-Lowering and Platelet Antiaggregant Plafibride on the Aging Process of Mice of the C57BL/6J Strain,” Meth and Find Exptl Clin Pharmacol 5(10):707-714, 1983.
Cameron, N.E. et al. “Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats”,Diabetologia; 1992; 35:946-950.
Cooper, M.E. et al., “The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation,” Diabetologia 43:660-664, 2000.
Corbett, J.A. et al. “Aminoguanidine, a Novel Inhibitor of Nitric Oxide Formation, Prevents Diabetic Vascular Dysfunction”,Diabetes, Apr. 1992; 41:552-556.
de Gruyter, W., Pschyrembel Klinisches Woerterbuch, 258:47-49, 1998.
Durany, N. et al. “Investigations on oxidative stress and therapeutical implications in dementia”,Eur. Arch. Psychiatry Clin. Neurosci., 1999; 249:Suppl. 3 III/68-III/73.
Ferrari, E. et al., “Effects of long-term treatment (4 years) with pentoxifylline on haemorheological changes and vascular complications in diabetic patients,” 5(1):26-39, 1987.
Grigoleit, H.G. et al., “Red Blood Cell Aging As a Model to Influence Pharmacologically The Red Cell Filterability,” Research in Experimental Medicine 179:249-254, 1981.
Guarnieri, G. et al., “Modulation of Protein Kinetics in Chronic Renal Failure,” Miner Electrolyte Metab 23:214-217, 1997.
Hirsch, J., “The reaction of some dicarbonyl sugars with aminoguanidine,” Carbohydrate Research 232:125-130, 1992.
Iwafune, Y. et al., “Clinical use of pentoxifylline in haemorrhagic disorders of the retina,” Pharmatherapeutica 2:429-438, 1980.
Jaku{overscore (s)}, V. et al. “Inhibition of Nonenzymatic Protein Glycation and Lipid Peroxidation by Drugs with Antioxidant Activity”,Life Sciences, 1999; 65(18-19):1991-1993.
Jyothirmayi, G.N. et al. “Effects of Metformin on Collagen Glycation and Diastolic Dysfunction in Diabetic Myocardium”,J. Cardiovasc. Pharmacol. Therapeut., 1998; 3(4):319-326.
Khalifah, R.G. et al. “Amadorins: Novel Post-Amadori Inhibitors of Advanced Glycation Reactions”,Biochem. Biophys. Res. Commun., 1999; 257:251-258.
Kochakian, M. et al. “Chronic Dosing with Aminoguanidine and Novel Advanced Glycosylation End Product-Formation Inhibitors Ameliorates Cross-Linking of Tail Tendon Collagen in STZ-Induced Diabetic Rats”,Diabetes, Dec. 1996; 45:1694-1700.
Lalezari, I. et al. “Synthesis and Investigation of Effects of 2-[4-[[(Arylamino)carbonyl]amino]phenoxy]-2-methylpropionic Acids on the Affinity of Hemoglobin for Oxygen: Structure-Activity Relationships”,J. Med. Chem., 1989; 32:2352-2357.
Lalezari, I. et al. “LR16, a compound with potent effects on the oxygen affinity of hemoglobin, on blood cholesterol, and on low density lipoprotein”,Proc. Natl. Acad. Sci. USA, Aug. 1988; 85:6117-6121.
Lee, Y. et al., “The Effect of Pentoxifylline on Current Perception Thresholds in Patients With Diabetic Sensory Neuropathy,” Journal of Diabetes and Its Complications 11:274-278, 1997.
Malik, N.S. and Meek, K.M. “The Inhibition of Sugar-Induced Structural Alterations in Collagen by Aspirin and Other Compounds”,Biochem. Biophys. Res. Commun., 1994; 199(2):683-686.
Marques, C. et al. “Bendazac decreased in vitro glycation of human lens crystallins. Decrease of in vitro protein glycation by bendazac”,Documenta Ophthalmologica, 1995; 90:395-404.
McCarty, M.F. “Nitric oxide deficiency, leukocyte activation, and resultant ischemia are crucial to the pathogenesis of diabetic retinopathy
europathy—preventive potential of antioxidants, essential fatty acids, chromium, ginkgolides, and pentoxifylline,” Medical Hypotheses 50:435-449, May 1998.
Menzel, E.J. et al. “Comparison of the effect of different inhibitors on the non-enzymatic glycation of rat tail tendons and bovine serum albumin”,Ann. Clin. Biochem., 1996; 33:241-248.
Miwa, I. et al. “Inhibition of Advanced Protein Glycation by 8-Quinolinecarboxylic Hydrazide”,Pharmacology, 1996; 52:314-320.
Morimitsu, Y. et al. “Protein Glycation Inhibitors from Thyme (Thymus vulgaris)”,Biosci. Biotech. Biochem., 1995; 59(11):2018-2021.
Münch, G. et al. “Influence of advanced glycation end-products and AGE-inhibitors on nucleation-dependent polymerization of β-amyloid peptide”,Biochimica et Biophysica Acta, 1997; 1360:17-29.
Münch, G. et al. “Advanced glycation endproducts in ageing and Alzheimer's disease”,Brain Research Reviews, 1997; 23:134-143.
Nakamura, S. et al. “Progression of Neph
Lalezari Iraj
Rahbar Samuel
Balasubramanian Venkataraman
City of Hope
Rothwell Figg Ernst & Manbeck P.C.
LandOfFree
Inhibitors of formation of advanced glycation endproducts... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of formation of advanced glycation endproducts..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of formation of advanced glycation endproducts... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3615023